Alterity Therapeutics Appoints New CFO
Ticker: PRNAF · Form: 6-K · Filed: Sep 30, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Sep 30, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: personnel-change, cfo-appointment, sec-filing
TL;DR
Alterity Therapeutics just hired a new CFO, Abby Macnish Niven.
AI Summary
Alterity Therapeutics Ltd. announced on September 30, 2024, the appointment of Abby Macnish Niven as Chief Financial Officer. This appointment is effective immediately and is detailed in Exhibit 99.1 of their 6-K filing.
Why It Matters
A change in CFO can signal shifts in financial strategy or operational focus for a company, impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing is a routine announcement of a personnel change and does not contain significant financial or operational disclosures that would inherently increase risk.
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — The company making the filing and the announcement.
- Abby Macnish Niven (person) — Newly appointed Chief Financial Officer.
- September 2024 (date) — The month during which this Form 6-K report is filed.
- 20240930 (date) — The filing date of the report.
FAQ
Who has been appointed as the new Chief Financial Officer of Alterity Therapeutics?
Abby Macnish Niven has been appointed as the new Chief Financial Officer.
What is the effective date of Abby Macnish Niven's appointment?
The filing indicates the appointment is effective immediately as of the filing date.
What type of SEC filing is this?
This is a Form 6-K filing, which is a Report of Foreign Private Issuer.
Which exhibit contains the announcement of the CFO appointment?
Exhibit 99.1 contains the announcement of the CFO appointment.
What is the principal executive office address of Alterity Therapeutics?
The principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Filing Stats: 194 words · 1 min read · ~1 pages · Grade level 12.5 · Accepted 2024-09-30 06:20:29
Filing Documents
- ea0216061-6k_alterity.htm (6-K) — 14KB
- ea021606101ex99-1_alterity.htm (EX-99.1) — 11KB
- image_001.jpg (GRAPHIC) — 13KB
- 0001213900-24-082900.txt ( ) — 44KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: September 30, 2024 2